Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study.

Wagner LM, Perentesis JP, Reid JM, Ames MM, Safgren SL, Nelson MD Jr, Ingle AM, Blaney SM, Adamson PC.

Pediatr Blood Cancer. 2010 Apr;54(4):538-45. doi: 10.1002/pbc.22407.

2.

Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors.

Wagner L, Turpin B, Nagarajan R, Weiss B, Cripe T, Geller J.

Pediatr Blood Cancer. 2013 Sep;60(9):1447-51. doi: 10.1002/pbc.24547.

PMID:
23630159
3.

Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors.

Wagner LM, Crews KR, Iacono LC, Houghton PJ, Fuller CE, McCarville MB, Goldsby RE, Albritton K, Stewart CF, Santana VM.

Clin Cancer Res. 2004 Feb 1;10(3):840-8.

4.

Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study.

Wagner LM, Villablanca JG, Stewart CF, Crews KR, Groshen S, Reynolds CP, Park JR, Maris JM, Hawkins RA, Daldrup-Link HE, Jackson HA, Matthay KK.

J Clin Oncol. 2009 Mar 10;27(8):1290-6. doi: 10.1200/JCO.2008.18.5918.

5.

Extended phase I evaluation of vincristine, irinotecan, temozolomide, and antibiotic in children with refractory solid tumors.

McNall-Knapp RY, Williams CN, Reeves EN, Heideman RL, Meyer WH.

Pediatr Blood Cancer. 2010 Jul 1;54(7):909-15. doi: 10.1002/pbc.22460.

PMID:
20405511
6.

Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study.

Bagatell R, Norris R, Ingle AM, Ahern C, Voss S, Fox E, Little AR, Weigel BJ, Adamson PC, Blaney S.

Pediatr Blood Cancer. 2014 May;61(5):833-9. doi: 10.1002/pbc.24874.

7.

Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.

DuBois SG, Marachelian A, Fox E, Kudgus RA, Reid JM, Groshen S, Malvar J, Bagatell R, Wagner L, Maris JM, Hawkins R, Courtier J, Lai H, Goodarzian F, Shimada H, Czarnecki S, Tsao-Wei D, Matthay KK, Mosse YP.

J Clin Oncol. 2016 Apr 20;34(12):1368-75. doi: 10.1200/JCO.2015.65.4889.

PMID:
26884555
8.

A phase I study of vincristine, irinotecan, temozolomide and bevacizumab (vitb) in pediatric patients with relapsed solid tumors.

Venkatramani R, Malogolowkin M, Davidson TB, May W, Sposto R, Mascarenhas L.

PLoS One. 2013 Jul 22;8(7):e68416. doi: 10.1371/journal.pone.0068416.

9.

Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a children's oncology group study.

McGregor LM, Spunt SL, Furman WL, Stewart CF, Schaiquevich P, Krailo MD, Speights R, Ivy P, Adamson PC, Blaney SM.

Cancer. 2009 Apr 15;115(8):1765-75. doi: 10.1002/cncr.24175.

10.

Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study.

Loghin ME, Prados MD, Wen P, Junck L, Lieberman F, Fine H, Fink KL, Metha M, Kuhn J, Lamborn K, Chang SM, Cloughesy T, DeAngelis LM, Robins IH, Aldape KD, Yung WK.

Clin Cancer Res. 2007 Dec 1;13(23):7133-8.

11.

Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors.

McGregor LM, Stewart CF, Crews KR, Tagen M, Wozniak A, Wu J, McCarville MB, Navid F, Santana VM, Houghton PJ, Furman WL, Rodriguez-Galindo C.

Pediatr Blood Cancer. 2012 Mar;58(3):372-9. doi: 10.1002/pbc.23075.

12.

Phase I. Trial of irinotecan and temozolomide in patients with solid tumors.

Jones SF, Gian VG, Greco FA, Miranda FT, Shipley DL, Thompson DS, Hainsworth JD, Toomey MA, Willcutt NT, Burris HA 3rd.

Oncology (Williston Park). 2003 May;17(5 Suppl 5):41-5.

PMID:
12800606
13.

[Irinotecan plus temozolomide in refractory or relapsed pediatric solid tumors].

Hernández-Marqués C, Lassaletta-Atienza A, Ruiz Hernández A, Blumenfeld Olivares JA, Arce Abaitua B, Cormenzana Carpio M, Madero Lopez L.

An Pediatr (Barc). 2013 Aug;79(2):68-74. doi: 10.1016/j.anpedi.2012.11.016. Spanish.

14.

Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study.

Jakacki RI, Hamilton M, Gilbertson RJ, Blaney SM, Tersak J, Krailo MD, Ingle AM, Voss SD, Dancey JE, Adamson PC.

J Clin Oncol. 2008 Oct 20;26(30):4921-7. doi: 10.1200/JCO.2007.15.2306.

15.

Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma.

Wagner LM, McAllister N, Goldsby RE, Rausen AR, McNall-Knapp RY, McCarville MB, Albritton K.

Pediatr Blood Cancer. 2007 Feb;48(2):132-9.

PMID:
16317751
16.

Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience.

Aguilera D, Mazewski C, Fangusaro J, MacDonald TJ, McNall-Knapp RY, Hayes LL, Kim S, Castellino RC.

Childs Nerv Syst. 2013 Apr;29(4):589-96. doi: 10.1007/s00381-012-2013-4.

17.

Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma.

Raciborska A, Bilska K, Drabko K, Chaber R, Pogorzala M, Wyrobek E, Polczyńska K, Rogowska E, Rodriguez-Galindo C, Wozniak W.

Pediatr Blood Cancer. 2013 Oct;60(10):1621-5. doi: 10.1002/pbc.24621.

PMID:
23776128
18.

Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial.

DuBois SG, Chesler L, Groshen S, Hawkins R, Goodarzian F, Shimada H, Yanik G, Tagen M, Stewart C, Mosse YP, Maris JM, Tsao-Wei D, Marachelian A, Villablanca JG, Matthay KK.

Clin Cancer Res. 2012 May 1;18(9):2679-86. doi: 10.1158/1078-0432.CCR-11-3201.

19.

Phase I study of bevacizumab plus irinotecan in pediatric patients with recurrent/refractory solid tumors.

Okada K, Yamasaki K, Tanaka C, Fujisaki H, Osugi Y, Hara J.

Jpn J Clin Oncol. 2013 Nov;43(11):1073-9. doi: 10.1093/jjco/hyt124.

20.

Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma.

DuBois SG, Allen S, Bent M, Hilton JF, Hollinger F, Hawkins R, Courtier J, Mosse YP, Matthay KK.

Br J Cancer. 2015 Feb 17;112(4):644-9. doi: 10.1038/bjc.2015.12.

Items per page

Supplemental Content

Support Center